Chronic Pain Clinical Trial
Official title:
Impact of Lifestyle Changes Via the Complete Health Improvement Program on Telomerase Activity and Telomere Length in Patients With Chronic Pain
| NCT number | NCT03056417 |
| Other study ID # | 14X145 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | January 10, 2017 |
| Est. completion date | May 2019 |
| Verified date | September 2020 |
| Source | Ohio University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The current project will use the Complete Health Improvement Program (CHIP) as an intervention for patients with chronic pain. CHIP is a nationally recognized program that encourages a diet of whole plant-based foods, moderate exercise, stress reduction, and social support. Patients with chronic pain who enroll in CHIP classes will be monitored and compared to patients with chronic pain who are not enrolled in CHIP classes. It is hypothesized that patients who complete CHIP will have increased telomerase activity and longer relative telomere length at follow-up when compared to those who do not enroll in the program. Chromosomes consist of DNA that contains the genetic makeup of an individual; and telomeres are the caps on these chromosomes that protect them from damage. Telomere shortening occurs normally with aging and once they are too short to replicate cellular death occurs. Telomerase is a ribonucleic protein that counterbalances this shortening by extending the ends of chromosomes. Research has shown that patients with chronic pain may have shorter telomeres relative to others of the same age. This study will investigate this association further.
| Status | Completed |
| Enrollment | 67 |
| Est. completion date | May 2019 |
| Est. primary completion date | May 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 40 Years to 70 Years |
| Eligibility | Inclusion Criteria: - 40-70 years old - Physician confirmed chronic pain diagnosis for at least 6 months Exclusion Criteria: - Pregnancy - Physical or mental condition that limits ability to provide consent or answer questionnaires |
| Country | Name | City | State |
|---|---|---|---|
| United States | Ohio University | Athens | Ohio |
| Lead Sponsor | Collaborator |
|---|---|
| Ohio University |
United States,
Drozek D, Diehl H, Nakazawa M, Kostohryz T, Morton D, Shubrook JH. Short-term effectiveness of a lifestyle intervention program for reducing selected chronic disease risk factors in individuals living in rural appalachia: a pilot cohort study. Adv Prev Med. 2014;2014:798184. doi: 10.1155/2014/798184. Epub 2014 Jan 16. — View Citation
Hassett AL, Epel E, Clauw DJ, Harris RE, Harte SE, Kairys A, Buyske S, Williams DA. Pain is associated with short leukocyte telomere length in women with fibromyalgia. J Pain. 2012 Oct;13(10):959-69. doi: 10.1016/j.jpain.2012.07.003. — View Citation
Li B, Comai L. Requirements for the nucleolytic processing of DNA ends by the Werner syndrome protein-Ku70/80 complex. J Biol Chem. 2001 Mar 30;276(13):9896-902. Epub 2001 Jan 4. — View Citation
Shcherbakova DM, Zvereva ME, Shpanchenko OV, Dontsova OA. [Telomerase: structure and properties of the enzyme, characteristics of the yeast telomerase]. Mol Biol (Mosk). 2006 Jul-Aug;40(4):580-94. Review. Russian. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Telomerase activity changes as a result of lifestyle change | Assessed via peripheral blood mononuclear cells | Change from baseline telomerase at 3 months | |
| Primary | Subjective pain ratings as a function of positive lifestyle modifications | Assessed via the Brief Pain Inventory - Short Form. Measures pain intensity from 0 to 10, 10 being pain as bad as you can imagine. Also measures the extent to which pain interferes with daily functioning (0 - 10 possible, with 10 indicating completely interferes). | Change from baseline subjective pain at 3 months | |
| Secondary | Relative telomere length changes as a result of lifestyle change | Assessed via whole blood samples | Change from baseline telomere length at 3 months | |
| Secondary | Relative telomere length changes as a result of lifestyle change at 1-year follow-up | Assessed via whole blood samples | Change from 3 month follow-up data of telomere length at 1-year | |
| Secondary | Fasting glucose changes as a result of lifestyle change | Assessed via whole blood samples | Change from baseline fasting glucose at 3 months | |
| Secondary | Fasting glucose changes as a result of lifestyle change at 1-year follow-up | Assessed via whole blood samples | Change from 3 month follow-up data of fasting glucose at 1-year | |
| Secondary | Fasting lipid profile (i.e., HDL, LDL, triglycerides) modification as a result of lifestyle change | Assessed via whole blood | change from baseline fasting lipids at 3 months | |
| Secondary | Fasting lipid profile (i.e., HDL, LDL, triglycerides) modification as a result of lifestyle change at 1-year follow-up | Assessed via whole blood | Change from 3 month follow-up data of fasting lipids at 1-year | |
| Secondary | C-reactive protein changes as a result of lifestyle change | Assessed via plasma | change from baseline C-reactive protein at 3 months | |
| Secondary | C-reactive protein changes as a result of lifestyle change at 1-year follow-up | Assessed via plasma | Change from 3 month follow-up data of C-reactive protein at 1-year | |
| Secondary | Overall well-being changes as a result of lifestyle change | The RAND-36 item short form survey. High score indicates more favorable health state. Minimum score 0 Maximum score 100. | change from baseline overall well-being at 3 months | |
| Secondary | Overall well-being changes as a result of lifestyle change at 1-year follow-up | The RAND-36 item short form survey. High score indicates more favorable health state. Minimum score 0 Maximum score 100. | Change from 3 month follow-up data of overall well-being at 1-year | |
| Secondary | Perceived Stress changes as a result of lifestyle change | The 14-item Perceived Stress Scale. Minimum score 0 Maximum score 40. Higher scores indicate greater perceived stress. | change from baseline perceived stress at 3 months | |
| Secondary | Perceived Stress changes as a result of lifestyle change at 1-year follow-up | The 14-item Perceived Stress Scale. Minimum score 0 Maximum score 40. Higher scores indicate greater perceived stress. | Change from 3 month follow-up data of perceived stress at 1-year | |
| Secondary | Depressive symptom changes as a result of lifestyle change | Center for Epidemiological Studies Depression Scale. Higher score indicates greater depressed mood. Minimum score 0 Maximum score 60. | change from baseline depressed mood at 3 months | |
| Secondary | Depressive symptom changes as a result of lifestyle change at 1-year follow-up | Center for Epidemiological Studies Depression Scale. Higher score indicates greater depressed mood. Minimum score 0 Maximum score 60. | Change from 3 month follow-up data of depressed mood at 1-year | |
| Secondary | Perceived social support modification as a result of lifestyle change | Multidimensional Scale of Perceived Social Support. Higher score indicates greater perceived social support. Minimum score 1 Maximum score 7. | change from baseline perceived social support at 3 months | |
| Secondary | Perceived social support modification as a result of lifestyle change at 1-year follow-up | Multidimensional Scale of Perceived Social Support. Higher score indicates greater perceived social support. Minimum score 1 Maximum score 7. | Change from 3 month follow-up data of perceived social support at 1-year | |
| Secondary | Health-Promoting behavior change as a result of lifestyle modification | Health-Promoting Lifestyle Profile II questionnaire. Higher score indicate greater health promotion. Minimum score 1 Maximum score 4. | change from baseline health promoting behavior at 3 months | |
| Secondary | Health-Promoting behavior change as a result of lifestyle modification at 1-year follow-up | Health-Promoting Lifestyle Profile II questionnaire. Higher score indicate greater health promotion. Minimum score 1 Maximum score 4. | Change from 3 month follow-up data of health promoting behavior at 1-year | |
| Secondary | Telomerase activity changes as a result of lifestyle change at 1-year follow-up | Assessed via peripheral blood mononuclear cells | Change from 3 month follow-up data of telomerase activity at 1-year | |
| Secondary | Subjective pain ratings as a function of positive lifestyle modifications at 1-year follow-up | Assessed via the Brief Pain Inventory - Short Form. Measures pain intensity from 0 to 10, 10 being pain as bad as you can imagine. Also measures the extent to which pain interferes with daily functioning (0 - 10 possible, with 10 indicating completely interferes). | Change from 3 month follow-up data of subjective pain at 1-year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
| Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
| Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
| Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
| Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
| Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
| Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
| Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
| Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
| Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
| Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
| Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
| Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
| Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
| Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
| Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
| Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
| Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
| Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|